Efficacy and Safety of Pola-R-CHP Regimen in Patients with HIV-Related Diffuse Large B-Cell Lymphoma

Efficacy and Safety of Pola-R-CHP Regimen in Patients with HIV-Related Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Observational Real-World Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600125350

Enrollment

Unknown

Registered

2026-05-26

Start date

2026-06-01

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV-Related Diffuse Large B-Cell Lymphoma

Interventions

Pola-R-CHP treatment group:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Subjects must meet all of the following criteria: 1. Age >= 18 years; 2. Provision of signed Informed Consent Form (ICF); 3. Histologically confirmed diffuse large B-cell lymphoma (DLBCL) by tissue biopsy according to the World Health Organization (WHO) classification (including DLBCL, not otherwise specified [NOS], or unclassifiable DLBCL); 4. No prior treatment for lymphoma (except for glucocorticoids); 5. Positive for human immunodeficiency virus (HIV) antibody; 6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.

Exclusion criteria

Exclusion criteria: Subjects meeting any of the following criteria will be excluded from the study: 1. History of severe cardiac disease: New York Heart Association (NYHA) Class III or IV, congestive heart failure, myocardial infarction , cerebrovascular accident, unstable arrhythmia, unstable angina, or a history of multiple cardiovascular events within the past 3 months, or severe pulmonary disease. 2. Central nervous system (CNS) involvement by lymphoma. 3. Uncontrolled severe infection within 4 weeks prior to study enrollment, including bacterial, viral, fungal, mycobacterial, or other pathogen infections, or active tuberculosis. 4. Presence of an active malignancy that, in the investigator's judgment, may interfere with study results or affect survival, with the exception of non-melanoma skin cancer or stage 0 (in situ) cervical cancer, malignancies treated with curative intent and with no evidence of recurrence for > 2 years, or low-grade prostate cancer not requiring treatment. 5. Known hypersensitivity to Chinese hamster ovary (CHO) cell products, or any components of rituximab, polatuzumab vedotin, and/or the contrast media used in the study. 6. Pregnant or lactating women.

Design outcomes

Primary

Measure	Time frame
Investigator-assessed Complete Response Rate (CRR);	—

Secondary

Measure	Time frame
Objective Response Rate;Progression-Free Survival Rate;Overall Survival;Disease-Free Survival;Duration of Response;	—

Countries

China

Contacts

Public ContactLiu Yao

Chongqing University Cancer Hospital

648283926@qq.com+86 132 2868 4685

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026